ClinicalTrials.gg
CompletedNCT01775124DRAGONUpdated Sep 4, 2019Results posted

Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)

A Phase 4 interventional study of Ranibizumab in Neovascular Age-related Macular Degeneration, sponsored by Novartis Pharmaceuticals. Completed at 23 sites in China. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2019-09-04.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
332
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.

Enrollment
25th of 124
332 · median 64
Started
2013
with 8 others
Phase 4
33 of 125
none open now
Registered
73rd of 125
by date
Lead sponsor
15 of 125
Novartis Pharmaceuticals

Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 25th largest by enrollment of the 124 interventional ones that give a count, is one of 9 that started in 2013, is one of 33 in phase 4, and was the 73rd registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing ranibizumab in Macular Degeneration, or all of them as a file.
02

Study summary

The study evaluated the efficacy and safety of two different dosing regimens of ranibizumab (either monthly injections or injections as-needed based on the stability of a patient's vision) in Chinese patients with wet age-related macular degeneration (AMD) . This study was to provide long-term safety data in the treatment of Chinese patients with wet AMD.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration

Keywords

  • Macular degeneration,
  • age-related macular degeneration (ARMD),
  • vision loss,
  • macula damage,
  • retina damage,
  • dry macular degeneration,
  • wet macular degeneration,
  • AMD
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion criteria:

  • Patients with visual impairment due to neovascular AMD
  • A qualifying vision score at study entry Key Exclusion criteria
  • Active infection or inflammation either eye at study entry
  • Uncontrolled glaucoma in either eye
  • Any disorder in the study eye which may affect vision
  • Use of any systemic anti-vascular endothelial growth factor (VEGF)-drugs within 3 months prior to study entry
  • Previous treatment of the study eye for wet AMD
  • Any surgery in the study eye 3 months prior to or planned with 6 month after study entry
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
332 participants (actual)

Study arms

  • Experimental
    Ranibizumab 0.5 mg monthly

    Monthly intravitreal injections of ranibizumab 0.5 mg in the core treatment period and PRN intravitreal injections of the same dose guided by best-corrected visual acuity (BCVA) stabilization in the extension treatment period

    Drug: Ranibizumab

  • Experimental
    Ranibizumab 0.5 mg pro re nata (PRN)

    PRN intravitreal injections of ranibizumab 0.5 mg guided by best-corrected visual acuity (BCVA) stabilization in the 23 month treatment period

    Drug: Ranibizumab

Interventions

  • Intravitreal injections of 0.5 mg Ranibizumab

06

What researchers measure

Primary outcomes

  1. Average Change in Visual Acuity (Letters) From Month 3 to Month 4 Through Month 12

    Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like VA testing charts at a testing distance of 4 meters. This outcome measure describes the difference between the VA averaged across all visits from Month 4 through 12 and the Month 3 Level of Visual Acuity (Letters) of the Study Eye. The treatment regimen up to Month 3 is the same in both treatment groups.

    Time frame: Month 3 to month 4 through Month 12

Secondary outcomes

  1. Average Visual Acuity Change (Letters) From Month 3 to Month 4 Through Month 24

    Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes the difference between the average level of VA over all monthly post-baseline assessments from Month 4 to Month 24 and the Month 3 Level of VA. The treatment regimen up to Month 3 is the same in both treatment groups.

    Time frame: Month 3 to month 4 through Month 24

  2. Average Visual Acuity Change From Baseline to Month 1 Through Month 12 and Month 1 Through Month 24

    Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes the difference between VA averaged across all visits from Month 1 through Month 12 (24) and the baseline VA level

    Time frame: Baseline to Month 24

  3. Change From Baseline in Visual Acuity (Letters) of the Study Eye Over Time

    Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes the change in visual acuity at each visit compared to baseline

    Time frame: Baseline to 24 months

  4. Number of Patients With a BCVA Improvement of ≥5, ≥10, ≥15, and ≥30 Letters From Baseline to Month 24

    Visual acuity (VA) was at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes for each post-baseline month whether or not a patient improved by equal or more than 5, 10, 15,or 30 letters of VA as compared to baseline.

    Time frame: Baseline to Month 24

  5. Number of Patients With a BCVA Loss of 15 Letters in the Study Eye Over Time

    Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes for each post-baseline month whether or not a patient lost less than 15 letters of VA as compared with baseline.

    Time frame: Baseline to Month 24

  6. Number of Patients With a Best Corrected Visual Acuity (BCVA) of More of 73 Letters or More

    Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes for Month 12 and Month 24 whether a patient had a VA score of 73 or more letters

    Time frame: Month 12 and 24

  7. Change From Baseline in Central Sub-Field Thickness (CSFT) of the Study Eye Over Time to Month 12 and Month 24

    Optical coherence tomography(OCT) was used to assess CSFT (Central Sub-Field Thickness) representing the average retinal thickness of the circular area within 1 mm diameter around the foveal center. The Ns in the rows is the number of patients with a value for both baseline and the specific post-baseline visit

    Time frame: Baseline to Month 24

  8. Duration of Ranibizumab Treatment Free Interval in the Study Eye up to Month 24

    This outcome measure describes duration of treatment-free intervals. Treatment-free interval is defined as the number of visits (whether attended or not) where ranibizumab was not administered. n= the number of patients who had at least one ranibizumab treatment interruption

    Time frame: up to month 24

  9. Duration of Ranibizumab Treatment Free Interval in the Study Eye Prior to Month 12

    This outcome measure describes duration of treatment-free intervals prior to month 12. Treatment-free interval is defined as the number of visits (whether attended or not) where ranibizumab was not administered. n= the number of patients who had at least one ranibizumab treatment interruption Treatment-free interval is analyzed in the Ranibizumab 0.5 mg PRN group only. It is not analyzed in the Ranibizumab 0.5 mg monthly group because, by protocol design, these participants receive treatment monthly. Therefore, the analysis does not apply to this group.

    Time frame: prior to month 12

  10. Duration of Active Treatment Phase Prior to Month 12

    Time frame: Prior to month 12

  11. Duration of Active Treatment Phase up to Month 24

    Time frame: up to month 24

07

Results

Posted Feb 12, 2018

Participant flow

Core Period
Participant flow — Core Period
MilestoneRanibizumab 0.5 mg MonthlyRanibizumab 0.5 mg PRN
Started168166
Full analysis set167166
Per protocol set157155
Safety set166166
Completed157156
Not completed1110
Withdrew: Disease progression01
Withdrew: Physician decision11
Withdrew: Death01
Withdrew: Administrative problems10
Withdrew: Withdrawal by subject42
Withdrew: Adverse event55
Extension Period
Participant flow — Extension Period
MilestoneRanibizumab 0.5 mg MonthlyRanibizumab 0.5 mg PRN
Started157156
Completed145138
Not completed1218
Withdrew: Adverse event32
Withdrew: Physician decision02
Withdrew: Administrative problems01
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject912

Outcome measures

PrimaryAverage Change in Visual Acuity (Letters) From Month 3 to Month 4 Through Month 12

Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like VA testing charts at a testing distance of 4 meters. This outcome measure describes the difference between the VA averaged across all visits from Month 4 through 12 and the Month 3 Level of Visual Acuity (Letters) of the Study Eye. The treatment regimen up to Month 3 is the same in both treatment groups.

Time frame:
Month 3 to month 4 through Month 12
Reported as:
Mean · Letters
Average Change in Visual Acuity (Letters) From Month 3 to Month 4 Through Month 12
LettersRanibizumab 0.5 mg MonthlyRanibizumab 0.5 mg PRN
Average Change in Visual Acuity (Letters) From Month 3 to Month 4 Through Month 123.3 ± 5.611.7 ± 6.87
Statistical analysis
  • Ranibizumab 0.5 mg Monthly vs Ranibizumab 0.5 mg PRN · ANOVA · Mean difference (final values): -1.6 · 95% CI -2.95 to -0.2
SecondaryAverage Visual Acuity Change (Letters) From Month 3 to Month 4 Through Month 24

Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes the difference between the average level of VA over all monthly post-baseline assessments from Month 4 to Month 24 and the Month 3 Level of VA. The treatment regimen up to Month 3 is the same in both treatment groups.

Time frame:
Month 3 to month 4 through Month 24
Reported as:
Mean · Letters
Average Visual Acuity Change (Letters) From Month 3 to Month 4 Through Month 24
LettersRanibizumab 0.5 mg MonthlyRanibizumab 0.5 mg PRN
Average Visual Acuity Change (Letters) From Month 3 to Month 4 Through Month 243.7 ± 7.362.2 ± 7.95
SecondaryAverage Visual Acuity Change From Baseline to Month 1 Through Month 12 and Month 1 Through Month 24

Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes the difference between VA averaged across all visits from Month 1 through Month 12 (24) and the baseline VA level

Time frame:
Baseline to Month 24
Reported as:
Mean · Letters
Average Visual Acuity Change From Baseline to Month 1 Through Month 12 and Month 1 Through Month 24
LettersRanibizumab 0.5 mg MonthlyRanibizumab 0.5 mg PRN
Average Month 1 through month 1210.1 ± 9.378.1 ± 10.95
Average Month 1 through month 2411.0 ± 10.288.9 ± 11.95
SecondaryChange From Baseline in Visual Acuity (Letters) of the Study Eye Over Time

Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes the change in visual acuity at each visit compared to baseline

Time frame:
Baseline to 24 months
Reported as:
Mean · letters
Change From Baseline in Visual Acuity (Letters) of the Study Eye Over Time
lettersRanibizumab 0.5 mg MonthlyRanibizumab 0.5 mg PRN
Month 14.3 ± 6.753.4 ± 8.74
Month 26.8 ± 8.026.3 ± 9.94
Month 38.0 ± 9.387.2 ± 11.48
Month 49.3 ± 10.527.9 ± 11.67
Month 59.9 ± 10.718.4 ± 11.66
Month 610.7 ± 10.928.7 ± 12.33
Month 711.4 ± 10.498.5 ± 13.01
Month 811.3 ± 11.068.8 ± 12.53
Month 911.8 ± 10.909.2 ± 12.83
Month 1012.4 ± 11.249.4 ± 12.84
Month 1112.5 ± 10.909.6 ± 12.89
Month 1212.3 ± 11.479.6 ± 13.06
Month 1312.2 ± 12.049.9 ± 12.98
Month 1412.1 ± 12.1810.0 ± 13.29
Month 1512.2 ± 12.199.9 ± 13.56
Month 1612.3 ± 11.5910.0 ± 13.64
Month 1712.1 ± 11.9410.4 ± 13.78
Month 1811.8 ± 12.3110.1 ± 13.25
Month 1912.1 ± 12.439.8 ± 14.54
Month 2012.1 ± 12.709.8 ± 14.74
Month 2111.9 ± 13.179.6 ± 14.73
Month 2211.3 ± 13.199.5 ± 15.26
Month 2311.5 ± 13.239.2 ± 15.13
Month 2411.3 ± 13.729.3 ± 15.48
SecondaryNumber of Patients With a BCVA Improvement of ≥5, ≥10, ≥15, and ≥30 Letters From Baseline to Month 24

Visual acuity (VA) was at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes for each post-baseline month whether or not a patient improved by equal or more than 5, 10, 15,or 30 letters of VA as compared to baseline.

Time frame:
Baseline to Month 24
Reported as:
Number · Patients
Number of Patients With a BCVA Improvement of ≥5, ≥10, ≥15, and ≥30 Letters From Baseline to Month 24
PatientsRanibizumab 0.5 mg MonthlyRanibizumab 0.5 mg PRN
Month 1 Gain of >=5 letters7565
Month 1 Gain of >=10 letters2731
Month 1 Gain of >=15 letters1117
Month 1 Gain of >=30 letters11
Month 2 Gain of >=5 letters9895
Month 2 Gain of >=10 letters5448
Month 2 Gain of >=15 letters2832
Month 2 Gain of >=30 letters11
Month 3 Gain of >=5 letters107100
Month 3 Gain of >=10 letters7160
Month 3 Gain of >=15 letters4037
Month 3 Gain of >=30 letters14
Month 4 Gain of >=5 letters115100
Month 4 Gain of >=10 letters8075
Month 4 Gain of >=15 letters5346
Month 4 Gain of >=30 letters34
Month 5 Gain of >=5 letters114109
Month 5 Gain of >=10 letters8872
Month 5 Gain of >=15 letters5946
Month 5 Gain of >=30 letters45
Month 6 Gain of >=5 letters124108
Month 6 Gain of >=10 letters8675
Month 6 Gain of >=15 letters6044
Month 6 Gain of >=30 letters69
Month 7 Gain of >=5 letters127114
Month 7 Gain of >=10 letters8970
Month 7 Gain of >=15 letters6350
Month 7 Gain of >=30 letters510
Month 8 Gain of >=5 letters129110
Month 8 Gain of >=10 letters8974
Month 8 Gain of >=15 letters6654
Month 8 Gain of >=30 letters67
Month 9 Gain of >=5 letters126107
Month 9 Gain of >=10 letters9578
Month 9 Gain of >=15 letters6957
Month 9 Gain of >=30 letters611
Month 10 Gain of >=5 letters128116
Month 10 Gain of >=10 letters9575
Month 10 Gain of >=15 letters7453
Month 10 Gain of >=30 letters811
Month 11 Gain of >=5 letters130115
Month 11 Gain of >=10 letters9777
Month 11 Gain of >=15 letters7856
Month 11 Gain of >=30 letters711
Month 12 Gain of >=5 letters129114
Month 12 Gain of >=10 letters9782
Month 12 Gain of >=15 letters6952
Month 12 Gain of >=30 letters711
Month 13 Gain of >=5 letters127118
Month 13 Gain of >=10 letters9692
Month 13 Gain of >=15 letters6756
Month 13 Gain of >=30 letters911
Month 14 Gain of >=5 letters124117
Month 14 Gain of >=10 letters10088
Month 14 Gain of >=15 letters7065
Month 14 Gain of >=30 letters913
Month 15 Gain of >=5 letters126112
Month 15 Gain of >=10 letters10484
Month 15 Gain of >=15 letters6862
Month 15 Gain of >=30 letters813
Month 16 Gain of >=5 letters126114
Month 16 Gain of >=10 letters10187
Month 16 Gain of >=15 letters7162
Month 16 Gain of >=30 letters711
Month 17 Gain of >=5 letters119116
Month 17 Gain of >=10 letters10287
Month 17 Gain of >=15 letters7162
Month 17 Gain of >=30 letters512
Month 18 Gain of >=5 letters121117
Month 18 Gain of >=10 letters10187
Month 18 Gain of >=15 letters6961
Month 18 Gain of >=30 letters613
Month 19 Gain of >=5 letters121115
Month 19 Gain of >=10 letters9488
Month 19 Gain of >=15 letters7562
Month 19 Gain of >=30 letters911
Month 20 Gain of >=5 letters116116
Month 20 Gain of >=10 letters9885
Month 20 Gain of >=15 letters7263
Month 20 Gain of >=30 letters1013
Month 21 Gain of >=5 letters120117
Month 21 Gain of >=10 letters9681
Month 21 Gain of >=15 letters7661
Month 21 Gain of >=30 letters1112
Month 22 Gain of >=5 letters116114
Month 22 Gain of >=10 letters9288
Month 22 Gain of >=15 letters6964
Month 22 Gain of >=30 letters1413
Month 23 Gain of >=5 letters119115
Month 23 Gain of >=10 letters9385
Month 23 Gain of >=15 letters7262
Month 23 Gain of >=30 letters813
Month 24 Gain of >=5 letters114116
Month 24 Gain of >=10 letters9583
Month 24 Gain of >=15 letters7360
Month 24 Gain of >=30 letters1113
SecondaryNumber of Patients With a BCVA Loss of 15 Letters in the Study Eye Over Time

Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes for each post-baseline month whether or not a patient lost less than 15 letters of VA as compared with baseline.

Time frame:
Baseline to Month 24
Reported as:
Number · Patients
Number of Patients With a BCVA Loss of 15 Letters in the Study Eye Over Time
PatientsRanibizumab 0.5 mg MonthlyRanibizumab 0.5 mg PRN
Month 1, Loss of < 15 letters164163
Month 2, Loss of < 15 letters163162
Month 3, Loss of < 15 letters160162
Month 4, Loss of < 15 letters161162
Month 5, Loss of < 15 letters160160
Month 6, Loss of < 15 letters162160
Month 7, Loss of < 15 letters162158
Month 8, Loss of < 15 letters162159
Month 9, Loss of < 15 letters163159
Month 10, Loss of < 15 letters162161
Month 11, Loss of < 15 letters162161
Month 12, Loss of < 15 letters162160
Month 13, Loss of < 15 letters162157
Month 14, Loss of < 15 letters161158
Month 15, Loss of < 15 letters162159
Month 16, Loss of < 15 letters163159
Month 17, Loss of < 15 letters161157
Month 18, Loss of < 15 letters159157
Month 19, Loss of < 15 letters162155
Month 20, Loss of < 15 letters161155
Month 21, Loss of < 15 letters157155
Month 22, Loss of < 15 letters160154
Month 23, Loss of < 15 letters158153
Month 24, Loss of < 15 letters158153
SecondaryNumber of Patients With a Best Corrected Visual Acuity (BCVA) of More of 73 Letters or More

Visual acuity (VA) was assessed at every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. This outcome measure describes for Month 12 and Month 24 whether a patient had a VA score of 73 or more letters

Time frame:
Month 12 and 24
Reported as:
Number · Patients
Number of Patients With a Best Corrected Visual Acuity (BCVA) of More of 73 Letters or More
PatientsRanibizumab 0.5 mg MonthlyRanibizumab 0.5 mg PRN
Month 12>=73 letters6856
Month 24>=73 letters6359
SecondaryChange From Baseline in Central Sub-Field Thickness (CSFT) of the Study Eye Over Time to Month 12 and Month 24

Optical coherence tomography(OCT) was used to assess CSFT (Central Sub-Field Thickness) representing the average retinal thickness of the circular area within 1 mm diameter around the foveal center. The Ns in the rows is the number of patients with a value for both baseline and the specific post-baseline visit

Time frame:
Baseline to Month 24
Reported as:
Mean · microns
Change From Baseline in Central Sub-Field Thickness (CSFT) of the Study Eye Over Time to Month 12 and Month 24
micronsRanibizumab 0.5 mg MonthlyRanibizumab 0.5 mg PRN
Month 1-112.8 ± 117.95-108.7 ± 124.93
Month 2-141.1 ± 126.44-130.4 ± 145.58
Month 3-141.3 ± 127.47-141.2 ± 161.88
Month 4-150.4 ± 131.71-134.5 ± 158.88
Month 5-155.2 ± 134.58-131.5 ± 155.98
Month 6-158.6 ± 135.37-138.3 ± 159.07
Month 7-156.9 ± 136.61-137.9 ± 165.24
Month 8-165.4 ± 135.59-142.2 ± 165.76
Month 9-165.1 ± 136.04-143.3 ± 176.68
Month 10-165.9 ± 136.03-152.5 ± 177.11
Month 11-166.6 ± 140.62-152.5 ± 175.56
Month 12-166.5 ± 143.85-155.7 ± 173.19
Month 13-160.3 ± 142.02-151.4 ± 168.89
Month 14-159.9 ± 144.14-153.2 ± 167.81
Month 15-156.9 ± 152.33-158.1 ± 169.56
Month 16-155.9 ± 154.82-158.1 ± 173.23
Month 17-161.8 ± 155.18-156.8 ± 167.89
Month 18-159.5 ± 159.78-156.7 ± 174.88
Month 19-158.5 ± 163.82-154.8 ± 177.49
Month 20-157.6 ± 161.04-152.1 ± 173.30
Month 21-155.2 ± 160.03-151.9 ± 171.95
Month 22-156.8 ± 161.35-146.5 ± 176.83
Month 23-159.4 ± 163.58-148.3 ± 185.62
Month 24-167.7 ± 163.12-153.2 ± 178.22
SecondaryDuration of Ranibizumab Treatment Free Interval in the Study Eye up to Month 24

This outcome measure describes duration of treatment-free intervals. Treatment-free interval is defined as the number of visits (whether attended or not) where ranibizumab was not administered. n= the number of patients who had at least one ranibizumab treatment interruption

Time frame:
up to month 24
Reported as:
Mean · Months
Duration of Ranibizumab Treatment Free Interval in the Study Eye up to Month 24
MonthsRanibizumab 0.5 mg MonthlyRanibizumab 0.5 mg PRN
First treatment free interval (n=99,144)2.9 ± 2.383.7 ± 4.67
Second treatment free interval (n=49,112)2.1 ± 1.513.3 ± 3.48
Third treatment free interval (n=12,78)1.5 ± 0.523.0 ± 2.67
SecondaryDuration of Ranibizumab Treatment Free Interval in the Study Eye Prior to Month 12

This outcome measure describes duration of treatment-free intervals prior to month 12. Treatment-free interval is defined as the number of visits (whether attended or not) where ranibizumab was not administered. n= the number of patients who had at least one ranibizumab treatment interruption Treatment-free interval is analyzed in the Ranibizumab 0.5 mg PRN group only. It is not analyzed in the Ranibizumab 0.5 mg monthly group because, by protocol design, these participants receive treatment monthly. Therefore, the analysis does not apply to this group.

Time frame:
prior to month 12
Reported as:
Mean · Months
Duration of Ranibizumab Treatment Free Interval in the Study Eye Prior to Month 12
MonthsRanibizumab 0.5 mg PRN
First treatment free interval (n=127)2.7 ± 2.22
Second treatment free interval (n=73)2.0 ± 1.29
Third treatment free interval (n=19)1.3 ± 0.67
SecondaryDuration of Active Treatment Phase Prior to Month 12
Time frame:
Prior to month 12
Reported as:
Mean · Months
Duration of Active Treatment Phase Prior to Month 12
MonthsRanibizumab 0.5 mg MonthlyRanibizumab 0.5 mg PRN
Duration of Active Treatment Phase Prior to Month 1210.5 ± 1.869.1 ± 2.76
SecondaryDuration of Active Treatment Phase up to Month 24
Time frame:
up to month 24
Reported as:
Mean · Months
Duration of Active Treatment Phase up to Month 24
MonthsRanibizumab 0.5 mg MonthlyRanibizumab 0.5 mg PRN
Duration of Active Treatment Phase up to Month 2418.0 ± 5.9917.1 ± 6.90

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab 0.5 mg Monthly—24/166 (14.5%)107/166 (64.5%)
Ranibizumab 0.5 mg PRN—24/166 (14.5%)87/166 (52.4%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventRanibizumab 0.5 mg MonthlyRanibizumab 0.5 mg PRN
Cerebral infarctionNervous system disorders4/1661/166
Angina pectorisCardiac disorders2/1660/166
Coronary artery diseaseCardiac disorders2/1661/166
Vitreous haemorrhageEye disorders0/1662/166
Lacunar infarctionNervous system disorders0/1662/166
Acute myocardial infarctionCardiac disorders0/1661/166
Angina unstableCardiac disorders1/1660/166
Atrial fibrillationCardiac disorders0/1661/166
Cardiac discomfortCardiac disorders0/1661/166
Cardiac failureCardiac disorders0/1661/166
Most frequent other events
Showing 10 of 58
Most frequent other events
EventRanibizumab 0.5 mg MonthlyRanibizumab 0.5 mg PRN
NasopharyngitisInfections and infestations24/16618/166
Conjunctival haemorrhageEye disorders21/16612/166
Upper respiratory tract infectionInfections and infestations14/1667/166
Intraocular pressure increasedInvestigations5/16612/166
Blood glucose increasedInvestigations10/1665/166
CoughRespiratory, thoracic and mediastinal disorders8/1667/166
HypertensionVascular disorders8/1668/166
Visual acuity reducedEye disorders7/1662/166
DizzinessNervous system disorders5/1667/166
Retinal haemorrhageEye disorders5/1666/166

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Ranibizumab 0.5 mg MonthlyRanibizumab 0.5 mg PRNTotal
Mean65.6 ± 8.4366.8 ± 8.3166.2 ± 8.38
Sex: Female, Male
Sex: Female, Male(Participants)Ranibizumab 0.5 mg MonthlyRanibizumab 0.5 mg PRNTotal
Female484795
Male119119238
08

Study locations

23 sites
  • Novartis Investigative Site
    Beijing, Beijing 100191, China
  • Novartis Investigative Site
    Beijing, Beijing 100730, China
  • Novartis Investigative Site
    Chongqing City, Chongqing 400042, China
  • Novartis Investigative Site
    Lanzhou, Gansu 730030, China
  • Novartis Investigative Site
    Harbin, Heilongjiang 150001, China
  • Novartis Investigative Site
    Wuhan, Hubei 430060, China
  • Novartis Investigative Site
    Wuhan, Hubei 430070, China
  • Novartis Investigative Site
    Changsha City, Hunan 410011, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210029, China
  • Novartis Investigative Site
    Nanchang, Jiangxi 330006, China
  • Novartis Investigative Site
    Shenyang, Liaoning 110011, China
  • Novartis Investigative Site
    Qingdao, Shandong 2666000, China
  • Novartis Investigative Site
    Taiyuan, Shanxi 030002, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Tianjin, Tianjin 300020, China
  • Novartis Investigative Site
    Tianjin, Tianjin 300070, China
  • Novartis Investigative Site
    Wenzhou, Zhejiang 325027, China
  • Novartis Investigative Site
    Beijing, 100044, China
  • Novartis Investigative Site
    Beijing, 100176, China
  • Novartis Investigative Site
    Chongqing, 400038, China
  • Novartis Investigative Site
    Shanghai, 200031, China
  • Novartis Investigative Site
    Shanghai, 200080, China
  • Novartis Investigative Site
    Shanghai, 200092, China
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2013 to primary completion in Nov 2015, 33 months.

Results were first posted in Feb 2018, 2 years 2 months after primary completion.

Of 24 industry-sponsored phase 4 interventional studies under Macular Degeneration, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 33 months is above that.

Counting every sponsor, half of 45 studies reached it within 26 months; a quarter within 14 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2013
First posted
Jan 24, 2013
StartActual
Feb 22, 2013
Primary completionActual
Nov 23, 2015
CompletionActual
Nov 23, 2015
Results first posted
Feb 12, 2018
Last update
Sep 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01775124
Responsible party
Sponsor
First posted
Jan 24, 2013
Start date
Feb 22, 2013
Primary completion
Nov 23, 2015
Completion
Nov 23, 2015
Results posted
Feb 12, 2018
Last update
Sep 4, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion